SCHEMBL3479649

SCHEMBL3479649

CN1CCN(c2ccc3ccccc3c2)c2ccc(-n3ncccc3=O)cc2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.47
HTR3A P46098 1/20 0.42
KCNH2 Q12809 1/20 0.39
CYP17A1 P05093 1/20 0.38
SCN9A Q15858 1/20 0.38
RAB9A P51151 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPK9 P45984 1/20 0.36
MAPK10 P53779 1/20 0.36
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
LMNA P02545 1/20 0.36
HTR6 P50406 1/20 0.35
GAA P10253 1/20 0.35
SLC6A2 P23975 4/20 0.35
SLC6A4 P31645 4/20 0.35
SLC6A3 Q01959 4/20 0.35
IDO1 P14902 1/20 0.35
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3479741 0.89 HRH3 (0.42) HRH3KCNH2SCN9ARAB9ASMN1; SMN2
SCHEMBL3222466 0.86 HRH3 (0.39) HRH3KCNH2SCN9ASLC6A2SLC6A4
SCHEMBL3235782 0.86 HRH3 (0.39) HRH3HTR3AKCNH2SCN9ARAB9A
SCHEMBL3231196 0.85 SLC6A2 (0.47) HRH3KCNH2SCN9AALDH1A1LMNA
SCHEMBL3479734 0.85 HRH3 (0.39) HRH3KCNH2SCN9AALDH1A1SLC6A2
SCHEMBL3479776 0.85 HRH3 (0.40) HRH3HTR3AKCNH2SCN9ARAB9A
SCHEMBL3479590 0.84 HRH3 (0.40) HRH3KCNH2SCN9ASMN1; SMN2ALDH1A1
SCHEMBL3228568 0.83 HTR3A (0.46) HTR3ACYP17A1SCN9ARAB9AALDH1A1
SCHEMBL3479528 0.82 HTR3A (0.45) HRH3HTR3ACYP17A1SCN9ANPC1
SCHEMBL3479759 0.78 SLC6A2 (0.44) HTR3ACYP17A1SCN9ARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D HRH3 84/4885HTR3A 30/4885KCNH2 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.